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INTRODUCTION:  Systemic  sclerosis  is a rare  and  progressive  multisystem  autoimmune  disorder  that  is
characterized  pathologically  by  vascular  abnormalities,  connective  tissue  sclerosis  and  atrophy  of skin
and various  internal  organs  (e.g.,  alimentary  tract, lungs,  heart,  kidney,  CNS), and autoantibodies.  With
an unknown  etiology,  Scleroderma  is  a  complex  polygenetic  disease.  A  recent  Genome  Wide  Association
Study  (GWAS)  conﬁrmed  a strong  association  with  the  Major  Histocompatibility  Complex  (MHC) and
autoimmunity.  We  provide  a case  scenario  along  with  a review  of  the  systems  involved  and  challenges
physicians  can  face  in  dealing  with  this  rare  disease.
CASE PRESENTATION:  Our  patient,  a known  case  of systemic  sclerosis,  was  admitted  with  a history  of  right
femur fracture  following  a fall.  We  highlight  the  medical,  anesthetic  and  surgical  challenges  faced  by  our
team  in the  management  of  this  patient.  We will  explain  the  stages  patient  faced in treatment  process
till  her  death.  We  combined  the case  report  with  detailed  literature  review  of this  rare  disease.
DISCUSSION:  Systemic  sclerosis  is a complex  disease  process  with  many  different  levels  of  system  involve-
ment.  Patient  needs  to  be  reviewed  thoroughly  in  preoperative  period  by  multidisciplinary  team  and
counseled  in  detail  about  the  difﬁculties  in  procedure,  risks  and  complications.
CONCLUSION:  Patient  with  scleroderma  presents  a challenge  to  the  surgical  team  and  anesthetist  and  a
multidisciplinary  approach  should  be  followed  with  all of these  patients  to avoid  catastrophic  results.
©  2017  Published  by Elsevier  Ltd on  behalf  of  IJS Publishing  Group  Ltd.  This  is  an  open  access  article
under  the CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Systemic sclerosis is a rare and progressive multisystem autoim-
mune disorder that is characterized pathologically by vascular
abnormalities, connective tissue sclerosis and atrophy of skin and
various internal organs (e.g., alimentary tract, lungs, heart, kidney,
CNS), and autoantibodies [1].
Systemic sclerosis has an incidence between 2.3 and 10 per mil-
lion population [2,3]. There is considerable regional variation, most
likely due to environmental changes [4]. The ratio of female to male
is between 3 and 6:1 depending on the source [4]. The peak onset
is in the fourth decade for females and usually later for males; the
overall age of presentation is between 20–60 yrs [3]. It is seen in
all races, but is less common in Asians [5]. Although most patients
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have long survival, some of them progress rapidly to death. Sixty
percent of deaths are secondary to heart or lung involvement and
(or) to pulmonary hypertension [6].
With an unknown etiology, Scleroderma is a complex polyge-
netic disease. A recent Genome Wide Association Study (GWAS)
conﬁrmed a strong association with the Major Histocompatibil-
ity Complex (MHC) and autoimmunity [7]. SSc can be clinically
sub-classiﬁed based on patterns of skin ﬁbrosis into limited and dif-
fuse forms, the distinctions principally being made by the extent of
cutaneous involvement, but also included are certain other clinical
and immunological features (Table 1) [8]. In addition, the majority
of SSc patients (90%) have circulating anti-nuclear autoantibodies
(ANA) [9]. The three most common autoantibodies (auto-Abs) are
anti-DNA topoisomerase I (topo I), anti-RNA polymerase III, and
anti-centromere antibodies, in which the ﬁrst two auto-Abs tend
to be associated with diffuse SSc, the last one being strongly corre-
lated with limited SSc, although these associations are not complete
[9].
To our knowledge, only few case reports have been published
about this rare disease from medical and anesthesia point of view
https://doi.org/10.1016/j.ijscr.2017.11.051
2210-2612/© 2017 Published by Elsevier Ltd on behalf of IJS Publishing Group Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.
org/licenses/by-nc-nd/4.0/).
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and even fewer about surgical implications and considerations
required.
We present a case review of a patient with systemic sclerosis
who was admitted to our university hospital tertiary care center,
with history of fracture of femur following a fall. We  intend to high-
light the anesthetic and surgical challenges faced by our team in the
management of this case.
The work has been reported in line with the SCARE criteria [10].
2. Case review
A 64 year old female patient, limited community ambulant with-
out walking support, known case of scleroderma, ischemic heart
disease, hypertension and hypothyroidism was admitted to our
hospital with a history of ground level fall complaining of pain
in right thigh and inability to bear weight on right leg. General
examination revealed tightness of lips and skin around the neck
and multiple telangiectasias. Local examination revealed tender-
ness without open wound at right thigh. Right and left feet had
non healing superﬁcial wounds with serous discharge. Distal pulses
were not palpable bilaterally. Both hands showed sclerodactyly and
digital pitting scars on multiple digits.
Her x-rays showed comminuted fracture at the diaphysis-
metaphysis junction of right femur (Fig. 1).
On preoperative assessment she had multiple problems includ-
ing Raynaud’s phenomenon and pulmonary hypertension. Her
ECHO showed EF of 55%. Her MPS  scan shows normally perfused LV
myocardium with normal size LV cavity and LVEF of 65% with no
wall motion abnormality. Prognostically it was a good study with
low probability for annual risk for major cardiac events.
Patient was on oral steroids for more than 20 years, in addition
to anti-hypertensive, thyroxin and cardiac medications. Family and
genetic history was unremarkable.
After discussing with anesthesia team and the patient, decision
was taken to proceed with open reduction and internal ﬁxation
with plate under spinal anesthesia. Intraoperative spinal anes-
thesia was difﬁcult and took longer than usual. She underwent
uneventful plating of the right femur with MIPO (minimally inva-
sive plate osteosynthesis) technique. Surgery was  performed by a
senior orthopedic consultant. Only stat dose of IV Hydrocortisone
100 mg  was given on immediate postoperative period and was  put
on IV Clindamycin and Ciproﬂoxacin until discharge. She was  given
subcutaneous enoxaparin 40 mg  QD. She tolerated the procedure
and remained comfortable on intravenous analgesics which were
switched to oral as we  faced difﬁculty in her canulation. Patient
was mobilized bed to chair non-weight bearing on ﬁrst postop-
erative day (POD). Her hospital stay was uneventful and she was
discharged on 5th POD.
On 14th POD, wound was ok and stitches were removed in clinic.
On same day she presented in ER because of wound dehiscence
and serous discharge. Wound was washed with normal saline and
pyodine and tagging sutures were applied and advised alternate
day dressing. She was also discharged on Table Augmentin 1Gm
Q12H.
On 3rd postoperative week she had foul smelling discharge
from surgical site and culture swab showed moderate growth of
Acinetobacter species. She underwent wound debridement and
arthrotomy under spinal anesthesia. About 20 ml  of frank pus
was drained and CS showed Acinetobacter species sensitive to
ciproﬂoxacin and meropenem. It was yellow in color and was clear.
Urine culture showed Enterococcus species and she was put on line-
zolid and meropenem. Subsequently relook debridement was done
in addition to antibiotic cement beads insertion. In this surgery
anesthetist faced difﬁculty in spinal anesthesia and had to convert it
to general anesthesia. She was put on meropenem, gentamycin and
doxycycline after consulting the infectious disease (ID) team. She
was also given Inj. Hydrocortisone 100 mg  IV stat and Inj. Enoxa-
parin.
Postoperatively she was shifted to special care. Multiple teams
were involved in postoperative care including the physician, ID
team, cardiologist, pulmonologist and endocrinologist. She was
diagnosed with atrial ﬁbrillation with low ejection fraction of 15%,
pulmonary edema and type II respiratory failure necessitating her
admission in ICU. Patient dropped GCS to 5/15 and she was intu-
bated and put on ventilator. Second day in ICU patient’s condition
improved, successfully extubated and shifted out of ICU.
Her health status deteriorated again with low cardiac output,
acute kidney injury, not maintaining oxygen saturation and she
was put on Bi-level Positive Airway Pressure (BiPAP). The patient
and family refused the intubation and patient developed cardiopul-
monary failure and expired.
3. Discussion
According to the criteria for diagnosis of scleroderma estab-
lished by the Subcommittee for Scleroderma Criteria of the
American Rheumatism Association (ARA), the patients should have
either:
• Scleroderma proximal to the digits, affecting limbs, face, neck or
trunk- this is the single major criterion; or
• At least two  minor criteria, consisting of:
 Sclerodactyly (localized thickening and tightness of the skin of
ﬁngers and toes causing them to curl and limit their mobility)
 Digital pitting scarring (DPS)
 Bilateral basal pulmonary ﬁbrosis
These criteria have 97% sensitivity and 98% speciﬁcity [11].
Systemic sclerosis is an often fatal disease that affects skin and
internal organs with variable degrees. Many factors, including envi-
ronmental factors, can lead to immunologic system disturbances
and vascular changes. It is important to realize that this widespread
disease does not involve all organs in any patient; in certain cases
it may  be limited to one or two  organs. Even when changes are
present in any one organ, they are not uniform [12]. From a system-
atic perspective patients with scleroderma may  have the following
manifestations:
3.1. Vascular
The earliest feature of SSc is usually, but not invariably, Ray-
naud’s phenomenon. It may  precede cutaneous changes by years,
this interval can be shorter in males –usually under a year- than in
females, in whom it is approximately 5 years, but may  be as long
as 30 years. Patients may  have digital ulcers and be unable to use
their hands to perform activities of daily living [12].
3.2. Cutaneous
Skin over the face and hands is most frequently involved, but
changes may  extend proximally to forearm and upper arm, upper
chest, abdomen and back. Lower extremity changes are not uncom-
mon. Changes in the dermis show hyalinization of collagen, often
with associated abnormalities in elastic tissues and reticulin. In one
study, no increase in skin thickness or its collagen content was
found. The thickness and collagen content of the clinically affected
forearm skin were usually decreased and with a normal collagen
density. It is concluded that the clinical impression of thickness and
toughness is due to binding down of the skin to deeper structures
[13]. Dermal thickening can result in ﬂexion contractures, ischemic
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Fig. 1. X-ray of right knee antero-posterior and lateral shoot through views showing comminuted fracture at the diaphysis-metaphysis junction.
ulcerations, and resorption of distal phalanges (Sclerodactyly and
microstomia). Calcium deposits occur in the skin of ﬁngers and
hands that may  break down to discharge to discharge chalky white
material (calcinosis cutis). Telangiectases are often seen over the
involved skin as well as oral mucosa; these may  cause excessive
bleeding when traumatized during intubation.
3.3. Musculoskeletal
Notable bone changes seen in SSc are resorption of terminal pha-
langes (Acro-osteolysis) associated with calcinosis. Approximately
70% of the patients show absorption, which may  be minimal and
only involve one terminal phalanx or be gross and involve sev-
eral phalanges up-to proximal phalanges. Erosive arthropathy with
“pestle and mortar” deformity of the distal interphalangeal joints
may  also be seen. Other changes include increased intraosseous
deposition of calcium [12]. Arthritic pain is often seen in early
stages of systemic sclerosis, and initial radiographic changes seen
are reminiscent of rheumatoid arthritis but less destructive. One
study showed the presence of radiological abnormalities including
periarticular osteoporosis, joint space narrowing, and erosions [14]
Avascular necrosis of head of femur, presumably resulting from
vasculitis, has been described [15]. Muscle weakness may  occur.
Muscles of the forearms and hands are often affected as well as
the proximal muscles. Electromyography is abnormal in 50% of the
cases early in the disease and reaches up to 93% in late disease [12].
3.4. Pulmonary
Pulmonary involvement frequently includes diffuse ﬁbrosis
associated with diffuse disease or pulmonary hypertension that is
associated with the limited disease or CREST syndrome [12]. Inter-
stitial lung disease is reported to occur, in up to 80% of patients with
scleroderma. Although, in the majority of the patients, the intersti-
tial lung involvement is sub clinical and asymptomatic in the early
stage; clinically signiﬁcant interstitial lung disease is observed in
approximately 40% of patients with systemic sclerosis and is a lead-
ing cause of morbidity and mortality [16]. Pulmonary function is
frequently abnormal while chest radiography shows no pathology
[17]. Most experts rely on a combination of pulmonary function
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tests for diagnosis of interstitial pulmonary disease. Pulmonary
hypertension and right-side heart failure have become the leading
cause of death in patients with SSc [18].
3.5. Gastro-intestinal
Esophageal dysmotility, gastro-paresis and intestinal bacterial
overgrowth are some of the most common gastrointestinal man-
ifestations seen in patients with systemic sclerosis. Esophagus is
involved in about 75% of all patients; making it the most frequently
affected part of gastrointestinal tract. Patients often complain of
dysphagia and gastric reﬂux. Stricture of the lower end of esopha-
gus is seen in 10% of the cases which is not necessarily associated
with gastro-esophageal reﬂux or hernia. Esophageal mucosal thin-
ning occurs, with ﬁbrotic thickening in the remaining layers. There
may be extensive mucosal ulceration and marked esophageal dila-
tion. Carcinoma of the esophagus has also been reported [19].
3.6. Cardiac
The resting ECG is abnormal in approximately 50% of the cases
along with presence of cold-induced changes [20]. Other ﬁndings
include arrhythmias, partial or complete heart block and sclerosis of
coronary arteries. General enlargement of the heart; left ventricular
hypertrophy or a triangular outline is the most frequent radiolog-
ical abnormalities seen on radiography. Cardiac ﬁbrosis has been
demonstrated using MRI  and CT scans [21].
3.7. Renal
Renal involvement was seen as proteinuria in 36%, hypertension
in 24%, azotemia in 19% and malignant hypertension in 7% of one
series [22]. Creatinine clearance is affected in about 40% of cases
[12].
3.8. Endocrine
The thyroid and parathyroid glands may  be involved in the
ﬁbrotic process and thymus may  show cortical changes [12].
Summary of the difference between diffuse and limited SSc is
shown in Table 1.
3.9. Drug therapy
Currently there is no standard treatment regimen for systemic
sclerosis; the treatment depends on the presentation. Corticos-
teroids have largely been used for treating connective tissue
disease, but their role remains controversial in treating SSc due
to lack of evidence of effectiveness. Nevertheless, low-dose corti-
costeroids may  reduce articular symptoms. Dexamethasone pulse
Table 1
Difference between diffuse and limited SSc.
Diffuse cutaneous SSc Limited cutaneous SSc
Short interval (<1 year) between the
onset of Raynaud’s phenomenon and
the development of skin changes
Long history of Raynaud’s
phenomenon
Truncal and peripheral skin
involvement
Limited skin involvement
Tendon friction rubs Calciﬁcation, telangiectasia, late
onset of pulmonary HTN
Pulmonary ﬁbrosis, renal failure,
gastrointestinal disease, myocardial
involvement
Capillary dilation visible in the nail
fold
Capillary drop-out visible in skin folds Anticentromere antibody positive
Scl-70 antibody positive
Anticentromere antibody- negative
therapy has been claimed useful in some patients [12]. Of particu-
lar interest in this review is that long-term treatment with steroids
poses an increased risk of osteoporosis, myopathy and delayed
wound healing. Agents that have been used with varying efﬁcacy
are cyclophosphamide, prednisone [23].
Surgeons and Anesthesiologists managing patients with SSc
must have experience and background about the pathogenesis,
clinical manifestations, systemic involvement, surgical and anes-
thetic considerations. The fact that every aspect of surgical and
anesthetic care may  be altered or hindered by the pathogenesis
of this disease should never be forgotten.
3.10. Pre-op preparation
Routine investigations should include a full blood count, urea
and electrolytes, chest X-ray, ECG and clotting screen. Lung function
tests, steroid cover and pretreatment with vitamin K may  be nec-
essary to avoid any events during or after surgery. Proper history
should be taken for presence of dysphagia, regurgitation, weight
loss and digital pallor.
Any anatomical changes should be assessed, such as skin
tightening of the face, ability to open mouth (ﬁbrosis of the tem-
poromandibular joint, reduced oral aperture), neck mobility and
presence of oral telangiectases in regard to the possibility of endo-
tracheal intubation. Prior to arrival in the O.R, the patient should
be treated with an antacid or H2-receptor antagonists to avoid
regurgitation and aspiration. To minimize peripheral vasoconstric-
tion the Operating room temperature should be maintained above
21 ◦C, and intravenous ﬂuids should be warmed before administra-
tion [18]. Thickened skin, vasoconstriction and ﬂexion contractures
often pose difﬁculty in intravenous access and noninvasive BP mon-
itoring. This situation may  necessitate the need for ultrasonic blood
pressure sensors or invasive monitoring and central venous access.
3.11. Intra-op considerations
The choice of anesthesia technique is variable and should be
guided by identiﬁcation of organ dysfunction. General anesthesia
can lead to problems such as difﬁculty of intubation and insertion of
an IV cannula or measuring blood pressure. Esophageal dysmotility
and lower esophageal sphincter incompetence may  increase the
risk of aspiration [24]. In cases where general anesthesia is the only
choice, awake ﬁber-optic intubation is preferred especially when
mouth opening is limited [25].
Patients with Progressive Systemic Sclerosis (PSS) may  require
monitoring of cardiac performance, including cardiac output, con-
Table 2
Common Features Associated with Progressive Systemic Sclerosis (PSS).
Common Features Associated with Progressive Systemic Sclerosis (PSS)
Raynaud’s phenomenon Dermal thickening, calciﬁcations,
contractures
Oral or nasal bleeding Skin tightening, microstomia,
decreased neck ﬂexibility
Ventricular hypertrophy, diastolic
dysfunction, conduction defects
coronary vasospasm
Telangiectasias
Hypertension, decreased renal
clearance
Esophageal dilatation, decreased LES
tone
Anesthetic Considerations Intestinal malabsorption
Peripheral vasoconstriction Restrictive pulmonary disease
Peripheral IV difﬁculties Myocardial ﬁbrosis,
Difﬁcult airway management Renal disease
Aspiration Decreased Vit K-dependent clotting
factors
Increased positive airway pressure,
increased oxygen concentration,
extubation delays
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tractility, pulmonary arterial, and left ventricular ﬁlling pressures
in the presence of myocardial ﬁbrosis or pulmonary hypertension
[18]. Common features associated with PSS in Table 2.
Many authors recommend regional anesthesia for elderly
patients, those with severe SSc, and with severe pulmonary dis-
ease undergoing surgery. It should be kept in mind that owing to
decreased circulation and ﬁbrosis of tissue, the duration of action
of local anesthetic may  be prolonged. Review of literature has
revealed that a smaller dose of local anesthesia is required [26].
4. Conclusion
Patient with scleroderma presents a challenge to the surgical
team and anesthetist and a multidisciplinary approach should be
followed with all of these patients to avoid catastrophic results.
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